Clinical trials: Depressive Episodes
Major Depressive Disorder, Single Episode, Unspecified
Attention Bias Modification Treatment for Major Depressive Disorder in Adolescents
In this study, we test whether a two-week 8-session neutral attention bias modification (ABM) training and a two-week 4-session positive ABM could reduce depressive symptoms relative to placebo controls in adolescents with major…
- Trial name
- NCT02078258
- Testing
- ABMT
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Hunan Normal University
Major Depressive Episode, Suicidal Behavior
Neuroinflammation, Serotonin, Impulsivity and Suicide
Suicide is a major health problem that causes annually a million death worlwide. In the stress-vulnerability model, suicidal behavior (SB) results from the interaction between an individual's predisposition (personality, family…
- Trial name
- NISIS (NCT02824081)
- Testing
- Blood sample
- Where
- France
- Volunteers
- 280 people
- Sponsor
- University Hospital, Montpellier
Major Depressive Episode Associated With Bipolar II Disorder
To Evaluate the Effects of NMRA-335140 on Symptoms of Major Depression in Participants With Bipolar II Disorder.
This is a randomized, double-blind, placebo-controlled pilot study aiming to evaluate the effects of NMRA-335140 on symptoms of major depression in adults with Bipolar (BP) II disorder.
- Trial name
- NCT06429722
- Testing
- NMRA-335140 80 mg
- Where
- 21 sites in United States
- Volunteers
- 18 people
- Sponsor
- Neumora Therapeutics, Inc.
Major Depressive Episode
Predict MDE Outcomes After MST
This trial attempts to explore the treatment outcome of magnetic seizure therapy (MST) for major depressive episode. Half of the participants will receive MST, while the other half will receive electroconvulsive therapy (ECT).
- Trial name
- NCT03841019
- Testing
- Magpro X100 + Option, ThymatronSystem Ⅳ Electroconvulsive System
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Shanghai Mental Health Center
Depression, Depressive Disorder
Study to Evaluate TNX-601 ER Monotherapy Versus Placebo in Patients With Major Depressive Disorder (MDD)
This is a Phase 2, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of TNX-601 ER monotherapy versus placebo in patients with Major Depressive Disorder (MDD).
- Conditions
- Depression, Depressive Disorder, Depressive Symptoms, Depressive Disorder, Major
- Trial name
- UPLIFT (NCT05686408)
- Testing
- TNX-601 ER
- Where
- 27 sites in United States
- Volunteers
- 132 people
- Sponsor
- Tonix Pharmaceuticals, Inc.
Major Depressive Disorder
Efficacy and Safety of Vortioxetine (Lu AA21004) in the Treatment of Patients With Major Depressive Disorder
The purpose of this study is to determine the efficacy and safety of vortioxetine, once daily (QD), in adults with major depressive disorder.
- Trial name
- NCT00672620
- Testing
- Vortioxetine, Duloxetine
- Where
- 38 sites in United States
- Volunteers
- 611 people
- Sponsor
- Takeda
Bipolar Disorder I, Bipolar Disorder II
A Study to Evaluate SAGE-217 in Participants With Bipolar I/II Disorder With a Current Major Depressive Episode
This is an open-label study evaluating the safety, tolerability, pharmacokinetics, and efficacy of SAGE-217 in the treatment of participants with bipolar I/II disorder with a current major depressive episode.
- Conditions
- Bipolar Disorder I, Bipolar Disorder II, Major Depressive Episode
- Trial name
- NCT03692910
- Testing
- SAGE-217
- Where
- 11 sites in United States
- Volunteers
- 35 people
- Sponsor
- Biogen
Unipolar Depression
Randomized Clinical Trial of an Exposure-based Cognitive Therapy for Depression
The purpose of this study is to investigate, if exposure-based cognitive therapy (EBCT) is at least as effective as the established cognitive-behavioral therapy and more effective in its long-term efficacy.
- Trial name
- NCT01012856
- Testing
- Cognitive-Behavioral Therapy for Depression, Exposure-Based Cognitive Therapy for Depression
- Where
- Switzerland
- Volunteers
- 142 people
- Sponsor
- University of Zurich
Major Depressive Episode
The RAFT ECT Study
Severe depression is devastating for those affected and is often associated with significant risk of suicide. Electroconvulsive therapy (ECT) is a highly effective acute treatment for severe depression, but its use and…
- Trial name
- RAFT-ECT (NCT05402657)
- Testing
- Frontoparietal Ultrabrief Right Unilateral (UBRUL-FP) electroconvulsive therapy, Temporoparietal Ultrabrief Right Unilateral (UBRUL-TP) electroconvulsive therapy
- Where
- 7 sites in United States, Australia
- Volunteers
- 156 people
- Sponsor
- The George Institute
Major Depressive Disorder, Major Depressive Disorder, Recurrent Episode, Severe
Practical Application of Accelerated iTBS for MDD
The goal of this observational study is to evaluate the feasibility and efficacy of accelerated iTBS in adults diagnosed with Major Depressive Disorder.
- Conditions
- Major Depressive Disorder, Major Depressive Disorder, Recurrent Episode, Severe, Major Depressive Disorder, Recurrent, Moderate
- Trial name
- NCT06113575
- Testing
- NeuroStar TMS
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Sonder Behavioral Health and Wellness
Major Depressive Disorder
Combination Deplin® and Antidepressant Therapy for a Major Depressive Episode (MDE)- a Retrospective Analysis
This is a retrospective chart review study to determine if Deplin® 7.5mg-15mg combined with an antidepressant is better than an antidepressant alone in adults with major depression.
- Trial name
- NCT01001559
- Testing
- L-methylfolate, Selective serotonin reuptake inhibitor (SSRI), Serotonin and norepinephrine reuptake inhibitor (SNRI)
- Where
- United States
- Volunteers
- 242 people
- Sponsor
- Pamlab, Inc.
Bipolar Disorder
Depressive Symptoms in Acute Manic Episode
Observational, non-interventional, transversal, multicenter, open label (No treatment is involved). The primary objective is to detect the prevalence of depressive symptoms in bipolar patients admitted to a psychiatric Unit due…
- Trial name
- MM1 (NCT00690248)
- Where
- 34 sites in Spain
- Volunteers
- 250 people
- Sponsor
- AstraZeneca
Unipolar Depression
Oral Fluency and the Response to Antidepressant Therapy in the Elderly With a Unipolar Depressive Episode
The study focuses on the identification of clinical, physiological and morphological markers that could predict the response to antidepressant in elderly suffering from unipolar depressive disorder.
- Trial name
- PREDICTage (NCT03227133)
- Testing
- Neuropsychological evaluations, Psychiatric interview, Cardiovascular risk assessment
- Where
- France
- Volunteers
- 42 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Major Depressive Disorder, Major Depressive Episode
Mobile Observation Of Depression
The primary aim of this project is to test if OCOsense glasses can function as a digital phenotyping tool derived from behavioural and physiological signals related to facial expression and motion recorded using the glasses.
- Conditions
- Major Depressive Disorder, Major Depressive Episode, Bipolar Disorder
- Trial name
- MOOD (NCT05815459)
- Testing
- OCOsense
- Where
- United Kingdom
- Volunteers
- 84 people
- Sponsor
- Emteq Ltd
Depression, Depressive Disorder
Reward Processing and Depressive Subtypes: Identifying Neural Biotypes
Deficits in motivation and pleasure are common in depression, and thought to be caused by alterations in the ways in which the brain anticipates, evaluates, and adaptively uses reward-related information.
- Conditions
- Depression, Depressive Disorder, Major Depressive Disorder, Major Depressive Episode
- Trial name
- NCT06080646
- Testing
- cross-sectional MRI and EEG assessments (NO INTERVENTION)
- Where
- United States
- Volunteers
- 158 people, healthy volunteers welcome
- Sponsor
- San Francisco Veterans Affairs Medical Center
Affective Psychosis, Bipolar, Mania
Non-interventional Study of Ziprasidone in the Treatment of Bipolar and Schizoaffective Disorders.
Assessment of ziprasidone safety and efficacy in the treatment of bipolar and schizoaffective disorders.
- Conditions
- Affective Psychosis, Bipolar, Mania, Manic-Depressive Psychosis
- Trial name
- NCT00454883
- Testing
- ziprasidone
- Volunteers
- 379 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Depression, Bipolar
A Study of Abilify® Tablet(Aripiprazole) as an Adjunctive Treatment in the Bipolar Depression
This is an 8-week, multicenter, randomized, double blind, placebo controlled study to evaluate the efficacy and safety of aripiprazole as an adjunctive treatment with mood stabilizer for the treatment of patients (outpatients or…
- Trial name
- APOLLO (NCT03423680)
- Testing
- Abilify 2, 5, 10, 15mg (Tablet)
- Where
- South Korea
- Volunteers
- 390 people
- Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
Major Depressive Disorder (MDD) With Insomnia
Efficacy of Chronotherapeutic Combination for Major Depressive Episode With Insomnia
Major Depressive Disorder (MDD) affects 5% of the global population and is the second leading cause of disability worldwide. Despite the widespread use of antidepressants, 50-60% of patients do not respond adequately after 8…
- Trial name
- CombiChronoS (NCT07120880)
- Testing
- AD + SHR + active LT and extended-release melatonin 2mg
- Where
- France
- Volunteers
- 184 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Major Depressive Disorder
Efficacy and Safety Study of BHV-7000 Monotherapy in Major Depression
The purpose of this study is to determine the efficacy and safety of BHV-7000 in participants with Major Depressive Disorder (MDD)
- Trial name
- NCT06419608
- Testing
- BHV-7000
- Where
- 62 sites in United States
- Volunteers
- 336 people
- Sponsor
- Biohaven Therapeutics Ltd.
Treatment-Resistant Depression
Study of Efficacy, Safety, Tolerability and Pharmacokinetics of MIJ821 in Participants With Treatment- Resistant Depression (TRD)
The main purpose of this study was to evaluate safety and efficacy of a single injection of MIJ821 in addition to standard of care (SoC) pharmacological anti-depressant treatment in participants with treatment-resistant…
- Trial name
- NCT05454410
- Testing
- MIJ821 Subcutaneous Injection 1 mg, MIJ821 Subcutaneous Injection 4 mg, MIJ821 Subcutaneous Injection 10 mg
- Where
- 16 sites in United States, Japan and 2 more
- Volunteers
- 60 people
- Sponsor
- Novartis Pharmaceuticals